Lipid Levels Tied to ALS Risk Lipid Levels Tied to ALS Risk
Elevated levels of high-density lipoprotein are associated with reduced risk for amyotrophic lateral sclerosis (ALS); higher total cholesterol to HDL ratio is linked to increased risk for ALS.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 14, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

An ALS Drug Shows Early Promise Against Alzheimer's
MONDAY, Aug. 2, 2021 -- Could a drug used to treat amyotrophic lateral sclerosis (ALS) help people with mild Alzheimer's disease? The results of a small new study suggest the strategy could work. Riluzole has been used for more than 20 years to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 2, 2021 Category: General Medicine Source Type: news

ALS Drug Riluzole Shows Early Promise Against Alzheimer's
MONDAY, Aug. 2, 2021 -- Could a drug used to treat amyotrophic lateral sclerosis (ALS) help people with mild Alzheimer's disease? The results of a small new study suggest the strategy could work. Riluzole has been used for more than 20 years to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 2, 2021 Category: General Medicine Source Type: news

Covid vaccines confirmed to cause Parkinson's, dementia symptoms
(Natural News) Former National Institutes of Health (NIH) contract scientist and Classen Immunotherapies proprietor J. Bart Classen has published a paper warning that there is strong potential for Wuhan coronavirus (Covid-19) mRNA “vaccines” to trigger Parkinson’s, dementia and a variety of other prion and chronic diseases. Alzheimer’s, amyotrophic lateral sclerosis (ALS), and multiple system atrophy... (Source: NaturalNews.com)
Source: NaturalNews.com - July 26, 2021 Category: Consumer Health News Source Type: news

How COVID-19 Long Haulers Could Change the U.S. Disability Benefits System
When COVID-19 began spreading in the U.S. in March 2020, McKale Santin was working at a nursing home in Burlington, Vermont. She and her coworkers didn’t yet know how deadly the virus would become, but she remembers feeling nervous as the first patients got sick and she was asked to examine them with only a surgical mask, not the more protective N95 mask that she wore to test for conditions like tuberculosis. One day, a patient pulled down her own mask to sneeze while Santin was conducting a respiratory assessment. Soon after, the woman became one of Vermont’s first people to die from COVID-19—and Santin...
Source: TIME: Health - July 20, 2021 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 feature Source Type: news

Mitsubishi Tanabe Pharma America Announces EXSERVAN(TM) (riluzole) is Now Available in the U.S. for the Treatment of ALS
New Innovative Orally Dissolving Film Designed to Help Meet the Needs of ALS Patients Who Have Difficulty Swallowing Some Medications JERSEY CITY, N.J., June 30, 2021 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc. (... Biopharmaceuticals, Neurology, Product Launch Mitsubishi Tanabe Pharma, EXSERVAN, riluzole, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 30, 2021 Category: Pharmaceuticals Source Type: news

Cedars-Sinai awarded $11.99 million for ALS clinical trial
(Cedars-Sinai Medical Center) Cedars-Sinai has been awarded $11.99 million by California's stem cell agency to launch a clinical trial testing a potential gene and stem cell therapy for amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 23, 2021 Category: Biology Source Type: news

Study finds abnormal response to cellular stress is associated with Huntington's disease
(University of California - Irvine) A new University of California, Irvine-led study finds that the persistence of a marker of chronic cellular stress, previously associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), also takes place in the brains of Huntington's disease (HD) patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2021 Category: International Medicine & Public Health Source Type: news

New Genetic Insights Into Cause of ALS
MONDAY, June 21, 2021 -- Researchers say they've identified a new gene associated with an increased risk of amyotrophic lateral sclerosis (ALS) -- and that their discovery could lead to improved treatments for the deadly disease. ALS -- also called... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 21, 2021 Category: General Medicine Source Type: news

New Gene Variants Identified That May Raise Risk for ALS
THURSDAY, June 17, 2021 -- Variants in TP73 are associated with risk for amyotrophic lateral sclerosis (ALS), according to a study published online June 16 in Neurology. Kristi L. Russell, from the University of Utah School of Medicine in Salt Lake... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 17, 2021 Category: Pharmaceuticals Source Type: news

Cell Reports publishes data supporting the importance of ion channel, Kv7.2/7.3 as a target in ALS
(LaVoieHealthScience) QurAlis Corporation today announced the publication of an article in Cell Reports titled Human Amyotrophic Lateral Sclerosis Excitability Phenotype Screen: Target Discovery and Validation by QurAlis founders Kasper Roet, Ph.D., Clifford Woolf, M.D., Ph.D., and Kevin Eggan, Ph.D., who pioneered a high-content, live-cell imaging screen using ALS patient-derived motor neurons in combination with a compound library generated by Pfizer to identify drug targets to treat hyperexcitability induced neurodegeneration in ALS patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 8, 2021 Category: International Medicine & Public Health Source Type: news

5 Minutes With ... Steve Kowalski, ALS Foundation board secretary
Steve Kowalski was diagnosed four years ago with amyotrophic lateral sclerosis (ALS). He is now board secretary of the Mass. chapter of The ALS Association, helping raise awareness, and funding, for research and resources for ALS patients and their families. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 3, 2021 Category: Health Management Authors: Jim Morrison Source Type: news

Scientists Discover Rare Form of ALS That Can Strike Kids
WEDNESDAY, June 2, 2021 -- A new form of amyotrophic lateral sclerosis (ALS) that affects children has been discovered by an international team of researchers. They used advanced genetic techniques to identify 11 such cases in children who had... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 2, 2021 Category: General Medicine Source Type: news

Amyotrophic lateral sclerosis presents a & quot;considerable & quot; economic burden
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Scientists discover a new genetic form of ALS in children
(NIH/National Institute of Neurological Disorders and Stroke) In a study of 11 medical-mystery patients, an international team of researchers led by scientists at the National Institutes of Health and the Uniformed Services University (USU) discovered a new and unique form of amyotrophic lateral sclerosis (ALS). Unlike most cases of ALS, the disease began attacking these patients during childhood, worsened more slowly than usual, and was linked to a gene, called SPTLC1, that is part of the body's fat production system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 31, 2021 Category: International Medicine & Public Health Source Type: news

Science Saturday: How regenerative medicine is advancing ALS research
May is?ALS Awareness Month, a time to reflect on the role of regenerative medicine research in advancing understanding and treatment of amyotrophic lateral sclerosis?(ALS) or Lou Gehrig's disease. This neurodegenerative disorder causes nerve cells in the brain and spinal cord to die, blocking signals to the muscles. That results in paralysis that robs a person [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 29, 2021 Category: Databases & Libraries Source Type: news

Consumer Health: What do you know about Lou Gehrig's disease?
May is ALS Awareness Month, which makes this a good time to learn more about Lou Gehrig's disease, which is also known as amyotrophic lateral sclerosis, or ALS. Amyotrophic lateral sclerosis is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. More than 5,000 people [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 23, 2021 Category: Databases & Libraries Source Type: news

Canadian doctors now investigating mysterious brain condition in some patients
(Natural News) Doctors in Canada have encountered patients exhibiting symptoms of a mysterious brain condition. The disease shares similarities with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Medical professionals surmise that environmental toxins are behind the unknown condition. Roger Ellis is a patient afflicted with the disease. The New Brunswick resident, who is in... (Source: NaturalNews.com)
Source: NaturalNews.com - May 19, 2021 Category: Consumer Health News Source Type: news

CNIO researchers discover the cause of neuronal death in a large proportion of familial ALS patients
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The researchers attribute the loss of motor neurons in patients with Amyotrophic Lateral Sclerosis (ALS) to a new mechanism that blocks any cellular reaction that involves nucleic acids (DNA or RNA)Many cellular processes involving nucleic acids fail in the motor neurons of ALS patients; the mechanism discovered by the CNIO group finally explains these widespread problems that have been reported for yearsThe paper is published this week in 'The EMBO Journal' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2021 Category: International Medicine & Public Health Source Type: news

Discovering the Secrets of Motor Neurons with Single Cell Sequencing
Researchers identify new motor neuron subgroups and gain insights into amyotrophic lateral sclerosis (ALS). (Source: The Scientist)
Source: The Scientist - May 5, 2021 Category: Science Tags: Podcasts Source Type: news

After pressure, Biogen to expand compassionate use for ALS drug
Following pressure by advocates for patients with amyotrophic lateral sclerosis, or ALS, Biogen has expanded its early access program to an experimental ALS drug called tofersen. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 27, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

After pressure, Biogen to expand compassionate use for ALS drug
Following pressure by advocates for patients with amyotrophic lateral sclerosis, or ALS, Biogen has expanded its early access program to an experimental ALS drug called tofersen. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 27, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Protein linked to ALS/Ataxia could play key role in other neurodegenerative disorders
(University of Utah Health) A new study suggests that some neurological disorders share a common underlying thread. Staufen1, a protein that accumulates in the brains of patients with certain neurological conditions, is linked to amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, along with other neurological disorders, including Alzheimer's, Parkinson's, and Huntington's disease, according to University of Utah Health scientists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news

Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
ION363, the first medicine to specifically target FUS-ALS, is among Ionis' wholly owned assets the company plans to commercialize ALS portfolio now includes four clinical-stage investigational antisense medicines designed to treat the root causes of gen... Biopharmaceuticals, Neurology Ionis Pharmaceuticals, amyotrophic lateral sclerosis, FUS-ALS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2021 Category: Pharmaceuticals Source Type: news

CRISPR-SNP-chip enables amplification-free electronic detection of single point mutations
(Keck Graduate Institute) Keck Graduate Institute (KGI) Assistant Professor and University of California, Berkeley Visiting Scientist Dr. Kiana Aran first introduced the CRISPR-Chip technology in 2019. Now just two years later, she has expanded on its application to develop CRISPR-SNP-Chip, which enables detection of single point mutations without amplification in Sickle Cell Disease and Amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 5, 2021 Category: Biology Source Type: news

Helixmith Announces First Patient Enrolled in Phase 2 Study of...
Helixmith announced today enrollment of the first patient in a new Phase 2A clinical trial, REViVALS-1A, targeting Amyotrophic Lateral Sclerosis (ALS) using Helixmith’s flagship gene therapy product...(PRWeb March 10, 2021)Read the full story at https://www.prweb.com/releases/helixmith_announces_first_patient_enrolled_in_phase_2_study_of_engensis_vm202_for_amyotrophic_lateral_sclerosis/prweb17786005.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 10, 2021 Category: Pharmaceuticals Source Type: news

Researchers reveal process behind harmful glial cell change in motor neurone disease
(The Francis Crick Institute) Scientists at the Francis Crick Institute and UCL have identified the trigger of a key cellular change in amyotrophic lateral sclerosis (ALS), a type of motor neurone disease. The findings could help develop new treatments for many neurological diseases with the same change, including Parkinson's and Alzheimer's. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2021 Category: Biology Source Type: news

ALS neuron damage reversed with new compound
(Northwestern University) Scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis), a swift and fatal neurodegenerative disease that paralyzes its victims. In ALS, movement-initiating nerve cells in the brain and muscle-controlling nerve cells in the spinal cord die. After administering the new compound,, the diseased brain neurons stopped degenerating so much that they became similar to healthy control neurons after 60 days of treatment. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 23, 2021 Category: International Medicine & Public Health Source Type: news

Researchers find evidence of protein folding at site of intracellular droplets
(University of Notre Dame) Researchers at the University of Notre Dame found that elevated concentrations of proteins within the droplets triggered a folding event, increasing the potential for protein aggregation -- or misfolding -- which has been linked to neurological diseases including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2021 Category: International Medicine & Public Health Source Type: news

Bringing innovation to rare disease patients in Europe
Why is Biogen focusing on rare diseases?  About 6,000 different rare diseases have been identified to date and these are estimated to affect 30 million people across Europe. It is essential that we collaborate across the medical community, industry, and governments to develop new therapies, explore new technologies and ensure equitable access to treatment. We must innovate across every aspect of treatment to transform the lives of people in these underserved communities.  At Biogen, we have shown that pioneering in neuroscience can change the course of treatment for certain rare diseases. We have transformed the ...
Source: EyeForPharma - February 17, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
For many of the 30 million people affected by rare disease in the EU, lack of effective treatments and discrepancies in access and diagnosis are still common issues. Strong political will, innovation and further cooperation between countries remain vital to improve outcomes and transform their quality of life.To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021.Andrea Corazza, Head of Brussels Liaison Office, Public Policy& Government Affairs, Biogen, says: “With this campaign, we want to help put...
Source: EyeForPharma - February 11, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Occupational therapy interventions in adults with multiple sclerosis or amyotrophic lateral sclerosis: a scoping review - De-Bernardi-Ojuel L, Torres-Collado L, Garc ía-de-la-Hera M.
This scoping review aims to describe occupational therapy interventions carried out with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) patients in occupational therapy. A peer review of the literature was conducted in different databases:... (Source: SafetyLit)
Source: SafetyLit - February 8, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

The Microglial Component of Amyotrophic Lateral Sclerosis The Microglial Component of Amyotrophic Lateral Sclerosis
The authors explore evidence for the contribution of microglia to neurotoxicity and neuroprotection in amyotrophic lateral sclerosis. Might elucidation of these processes lead to novel therapeutics?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Poor corticospinal motor neuron health is associated with increased symptom severity in the acute phase following repetitive mild TBI and predicts early ALS onset in genetically predisposed rodents - Alkaslasi MR, Cho NE, Dhillon NK, Shelest O, Haro-Lopez PS, Linaval NT, Ghoulian J, Yang AR, Vit JP, Avalos P, Ley EJ, Thomsen GM.
Traumatic brain injury (TBI) is a well-established risk factor for several neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, however, a link between TBI and amyotrophic lateral sclerosis (ALS) has not been clearly elucidate... (Source: SafetyLit)
Source: SafetyLit - February 6, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Imaging zebrafish movements in 3D to better understand ALS disease
(Institut national de la recherche scientifique - INRS) An interdisciplinary team of the Institut national de la recherche scientifique (INRS) used an innovative imaging technique for a better understanding of motor deficits in Amyotrophic Lateral Sclerosis (ALS). The researchers were able to follow the escape behaviour of normal and disease zebrafish models, in 3D. Their results have recently been published inOptica, the flagship journal of the Optical Society (OSA). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2021 Category: International Medicine & Public Health Source Type: news

Suicide among veterans with amyotrophic lateral sclerosis - Lund EM, Hostetter TA, Forster JE, Hoffmire CA, Stearns-Yoder KA, Brenner LA, Sohi MT.
INTRODUCTION: The purpose of this study was to estimate the risk of death by suicide for those with amyotrophic lateral sclerosis (ALS) seeking care within the Veteran Health Administration (VHA). METHODS: This was a retrospective, cohort study. Ex... (Source: SafetyLit)
Source: SafetyLit - January 25, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

New molecular structures associated with ALS
(University of Seville) Researchers from the University of Seville and the University of Pavia have identified a link between Amyotrophic Lateral Sclerosis (ALS) and the accumulation of DNA-RNA hybrids in the genome. The accumulation of these hybrids causes increased genomic damage and boosts genetic instability. This finding will make it possible to better understand the molecular basis of the disease, as well as to propose new solutions to curb it. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2021 Category: International Medicine & Public Health Source Type: news

BrainStorm Announces NurOwn(R) Expanded Access Program
NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASD... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2020 Category: Pharmaceuticals Source Type: news

Antiepileptic drug reduces motor neuron excitability in ALS
(Massachusetts General Hospital) The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital (MGH). In addition, the multi-site study involves the first clinical investigation of ALS using a drug identified through an induced pluripotent stem cell model. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 10, 2020 Category: International Medicine & Public Health Source Type: news

NIH researchers link cases of ALS and FTD to a Huntington's disease-associated mutation
(NIH/National Institute of Neurological Disorders and Stroke) A study led by researchers at the National Institutes of Health has made a surprising connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two disorders of the nervous system, and the genetic mutation normally understood to cause Huntington's disease. This large, international project, which included a collaboration between the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), opens a potentially new avenue for diagnosing and treating some individuals with FTD or ALS. (...
Source: EurekAlert! - Medicine and Health - December 4, 2020 Category: International Medicine & Public Health Source Type: news

Multi-center, multi-tracer PET studies harmonized to detect neuroinflammation in ALS
(Society of Nuclear Medicine and Molecular Imaging) A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease. Pooling data acquired from different scanners, different neuroinflammation positron emission tomography (PET) markers and different sites enhanced researchers' ability to detect neuroinflammation in ALS patients. This research was published in the November issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news

ALS Ice Bucket Challenge Co-Founder Pat Quinn Dead At 37
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p16").init({"mcp":"cbs","width":"100%","height":"100%","video":"4895420","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p16","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","job...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 23, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Syndicated CBSN Boston ALS Ice Bucket Challenge Pat Quinn Pete Frates Source Type: news

BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Dr. Merit Cudkowicz and Dr. Ralph Kern presentation will be featured in Oral Presentation in the Clinical Trials Platform Session Clinical experience with outpatient NurOwn® administration will be presented in poster session NEW YORK, Nov. 23, 20... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, Amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 23, 2020 Category: Pharmaceuticals Source Type: news

Pat Quinn, Who Promoted A.L.S. Ice Bucket Challenge, Dies at 37
Mr. Quinn, who learned he had A.L.S. a month after he turned 30, was credited with helping to make the ice-bucket videos a viral sensation that raised $220 million worldwide. (Source: NYT Health)
Source: NYT Health - November 23, 2020 Category: Consumer Health News Authors: Concepci ón de León Tags: Amyotrophic Lateral Sclerosis Deaths (Obituaries) Ice Bucket Challenge ALS Assn Research Frates, Pete Philanthropy Quinn, Pat Source Type: news

BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Clinical trial did not meet statistical significance in primary efficacy endpoint NurOwn® showed a clinically meaningful treatment response compared to placebo in a pre-specified subgroup CSF biomarker analyses confirmed NurOwn resulted in a stat... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, Amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2020 Category: Pharmaceuticals Source Type: news

Chris Pendergast, Who Fought A.L.S. Mile After Mile, Dies at 71
Living for 27 years with Lou Gehrig ’s disease (and beating the odds), he started Ride for Life, an annual trek that has raised millions for A.L.S. research. (Source: NYT Health)
Source: NYT Health - October 29, 2020 Category: Consumer Health News Authors: Sam Roberts Tags: Pendergast, Chris (1949-2020) Deaths (Obituaries) Amyotrophic Lateral Sclerosis Lou Gehrig ' s Disease ALS Ride for Life (Nonprofit) Philanthropy Source Type: news

A wearable sensor to help ALS patients communicate
(Massachusetts Institute of Technology) MIT researchers have designed a skin-like device that can be attached to the face and measure small movements such as a twitch or a smile. With this approach, patients with amyotrophic lateral sclerosis (ALS) could communicate a variety of sentiments with small movements that are measured and interpreted by the device. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - October 22, 2020 Category: International Medicine & Public Health Source Type: news

Investigational Drug May Prolong Survival in Patients With ALS
TUESDAY, Oct. 20, 2020 -- Long-term survival analysis shows that patients with earlier initiation of sodium phenylbutyrate-taurursodiol (PB-TURSO) treatment for amyotrophic lateral sclerosis (ALS) have longer median overall survival, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2020 Category: Pharmaceuticals Source Type: news

New Drug Could Extend Life for People With ALS
FRIDAY, Oct. 16, 2020 -- An experimental drug combination lengthens survival for patients with amyotrophic lateral sclerosis (ALS), new research shows. A previous clinical trial found that the two-drug combo -- called AMX0035 -- slowed progression... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 16, 2020 Category: General Medicine Source Type: news

Drug May Extend A.L.S. Patients' Lives by Several Months, Study Finds
The two-drug combination invented by college students is one of many potential therapies being tested for this paralyzing fatal condition. (Source: NYT Health)
Source: NYT Health - October 16, 2020 Category: Consumer Health News Authors: Pam Belluck Tags: Amyotrophic Lateral Sclerosis Drugs (Pharmaceuticals) Clinical Trials Research Amylyx Pharmaceuticals Inc Food and Drug Administration ALS Assn Cohen, Joshua B Klee, Justin your-feed-healthcare Source Type: news